Zydus Lifesciences Ltd has received final approval from the USFDA to market Colestipol Hydrochloride Tablets in the strength of 1mg (US RLD: Colestid). Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet.
Colestipol Hydrochloride is a highly complex macro molecule drug substance with little or no systemic absorption.
- Read more about Zydus receives final approval from USFDA for Colestipol Hydrochloride Tablets
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/zydus-receives-final-approval-from-usfda-for%20colestipol-hydrochloride-tablets
No comments:
Post a Comment